Hypertension and antihypertensive treatment in HIV-infected individuals. A longitudinal cohort study

References

• Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–2512.
   PubMed Web of Science ®Google Scholar
• Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, . Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506–512.
   PubMed Web of Science ®Google Scholar
• Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, . Ischemic heart disease in HIV-infected and HIV-uninfected individuals: A population-based cohort study. Clin Infect Dis. 2007;44:1625–1631.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Sabin CA, Weber R, d’Arminio MA, El-Sadr WM, Reiss P, . Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349: 1993–2003.
   PubMed Web of Science ®Google Scholar
• Riddler SA, Li X, Chu H, Kingsley LA, Dobs A, Evans R, . Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med. 2007;8:280–287.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Arch Intern Med. 2000;160:2050–2056.
   PubMed Web of Science ®Google Scholar
• Kuller LH, Tracy R, Belloso W, De WS, Drummond F, Lane HC, . Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5: e203.
   PubMed Web of Science ®Google Scholar
• Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51:268–273.
   PubMed Web of Science ®Google Scholar
• Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, . Low CD4 + T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51:435–447.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, . Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356: 1723–1735.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, . Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010;55:262–270.
   PubMed Web of Science ®Google Scholar
• Baekken M, Os I, Sandvik L, Oektedalen O. Hypertension in an urban HIV-positive population compared with the general population: Influence of combination antiretroviral therapy. J Hypertens. 2008;26:2126–2133.
   PubMed Web of Science ®Google Scholar
• Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: Results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis. 2003;22:731–736.
   PubMed Web of Science ®Google Scholar
• Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, . Hypertension among HIV patients: Prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens. 2003;21:1377–1382.
   PubMed Web of Science ®Google Scholar
• Jerico C, Knobel H, Montero M, Sorli ML, Guelar A, Gimeno JL, . Hypertension in HIV-infected patients: Prevalence and related factors. Am J Hypertens. 2005;18: 1396–1401.
   PubMed Web of Science ®Google Scholar
• Seaberg EC, Munoz A, Lu M, Detels R, Margolick JB, Riddler SA, . Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19:953–960.
   PubMed Web of Science ®Google Scholar
• Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, . Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: The Swiss HIV Cohort Study. HIV Med. 2006;7:404–410.
   PubMed Web of Science ®Google Scholar
• Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS. 2006;20:1019–1026.
   PubMed Web of Science ®Google Scholar
• Palacios R, Santos J, Garcia A, Castells E, Gonzalez M, Ruiz J, . Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Medicine. 2006;7:10–15.
   PubMed Web of Science ®Google Scholar
• Chow DC, Souza SA, Chen R, Richmond-Crum SM, Grandinetti A, Shikuma C. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials. 2003;4:411–416.
   PubMed Web of Science ®Google Scholar
• Thiebaut R, El-Sadr WM, Friis-Moller N, Rickenbach M, Reiss P, Monforte AD, . Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther. 2005;10:811–823.
   PubMed Web of Science ®Google Scholar
• Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, . 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–1187.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, III, Feldman HI, . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, . European guidelines on cardiovascular disease prevention in clinical practice: Full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1–S113.
   Google Scholar
• Westheim A, Klemetsrud T, Tretli S, Stokke HP, Olsen H. Blood pressure levels in treated hypertensive patients in general practice in Norway. Blood Press. 2001;10:37–42.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek W, Farsang C. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: The Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens. 2008;26:2064–2070.
   PubMed Web of Science ®Google Scholar
• Asferg C, Mogelvang R, Flyvbjerg A, Frystyk J, Jensen JS, Marott JL, . Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens. 2010;23:327–333.
   PubMed Web of Science ®Google Scholar
• Bombelli M, Facchetti R, Sega R, Carugo S, Fodri D, Brambilla G, . Impact of body mass index and waist circumference on the long-term risk of diabetes mellitus, hypertension, and cardiac organ damage. Hypertension. 2011.
   Google Scholar
• Stolarz-Skrzypek K, Kuznetsova T, Thijs L, Tikhonoff V, Seidlerova J, Richart T, . Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA. 2011;305: 1777–1785.
   PubMed Web of Science ®Google Scholar
• Rywik SL, Williams OD, Pajak A, Broda G, Davis CE, Kawalec E, . Incidence and correlates of hypertension in the Atherosclerosis Risk in Communities (ARIC) study and the Monitoring Trends and Determinants of Cardiovascular Disease (POL-MONICA) project. J Hypertens. 2000;18: 999–1006.
   Google Scholar
• Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: A cohort study. Lancet. 2001;358:1682–166.
   PubMed Web of Science ®Google Scholar
• Jung O, Bickel M, Ditting T, Rickerts V, Welk T, Helm EB, . Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity. Nephrol Dial Transplant. 2004;19:2250–2258.
   Google Scholar
• Medina-Torne S, Ganesan A, Barahona I, Crum-Cianflone NF. Hypertension is common among HIV-infected persons, but not associated with HAART. J Int Assoc Physicians AIDS Care (Chic ). 2011.
   Google Scholar
• Manner IW, Baekken M, Oektedalen O, Sandvik L, Os I. Effect of HIV duration on ambulatory blood pressure in HIV-infected individuals with high office blood pressure. Blood Press. 2010;19:188–195.
   PubMed Web of Science ®Google Scholar
• Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, . T cell activation is associated with lower CD4 + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534–1543.
   PubMed Web of Science ®Google Scholar
• Neuhaus J, Jacobs DR, Jr., Baker JV, Calmy A, Duprez D, La RA, . Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788–1795.
   PubMed Web of Science ®Google Scholar
• Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945–2951.
   PubMed Web of Science ®Google Scholar
• Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, . Inflammation, immunity, and hypertension. Hypertension. 2011;57:132–140.
   PubMed Web of Science ®Google Scholar
• Cattelan AM, Trevenzoli M, Sasset L, Rinaldi L, Balasso V, Cadrobbi P. Indinavir and systemic hypertension. AIDS. 2001;15:805–807.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d’Arminio MA, . Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179–1193.
   PubMed Web of Science ®Google Scholar
• EACS gulidelines, version 6.0. Web. 2011 Available from: http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacsguidelines-6.pdf
   Google Scholar
• Boccara F, Auclair M, Cohen A, Lefevre C, Prot M, Bastard JP, . HIV protease inhibitors activate the adipocyte renin angiotensin system. Antivir Ther. 2010;15: 363–375.
   PubMed Web of Science ®Google Scholar